BAT2206 (ustekinumab biosimilar) / Bio-Thera Solutions, Pharmapark, Hikma, Biomm 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BAT2206 (ustekinumab biosimilar) / Bio-Thera Solutions, Pharmapark, Hikma, Biomm
NCT04728360: Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Completed
3
556
RoW
BAT2206, Stelara (EU-sourced)
Bio-Thera Solutions
Plaque Psoriasis
10/22
07/23
2020-004504-33: Study to Compare Efficacy and Safety of BAT2206 with Stelara® in Patients with Moderate to Severe Plaque Psoriasis

Not yet recruiting
3
556
Europe
Recombinant Human Anti-IL12 Monoclonal Antibody, BAT2206, Solution for injection in pre-filled syringe, Stelara®
Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.
Moderate to Severe Plaque Psoriasis, chronic autoimmune disorder that causes the excessive buildup of skin cells, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
ChiCTR2000030273: A Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2206 Injection vs Ustekinumab Injection (Stelara) in Healthy Chinese Male Subjects

Not yet recruiting
1
270
 
BAT2206 injection, 45mg; Stelara (EU-licensed); 45mg; Stelara (US-licensed), 45mg
The First Hospital of Jinlin University; Bio-thera Solutions, Ltd., Self-finance
Psoriasis
 
 

Download Options